Non-viral retinal gene therapy: a review

Area of Science:

• Ophthalmology
• Genetics
• Biotechnology

Background:

• Retinal diseases are a leading cause of untreatable blindness globally.
• Genetic factors are implicated in many retinal conditions, highlighting gene therapy as a potential treatment.
• Current gene therapy strategies for the retina offer advantages over systemic drug delivery, including targeted expression and sustained therapeutic protein production.

Purpose of the Study:

• To explore the potential of non-viral gene therapy for treating retinal diseases.
• To address the challenges of nuclear localization and long-term transgene expression in non-viral gene delivery.
• To develop artificial gene delivery systems that mimic the efficiency of natural viral processes for retinal applications.

Main Methods:

• Review of viral and non-viral gene delivery mechanisms.
• Analysis of challenges in achieving stable transgene expression with non-viral vectors.
• Exploration of laboratory and molecular techniques for enhancing non-viral gene therapy efficacy.

Main Results:

• Viral vectors offer efficient gene delivery through mechanisms like receptor-mediated uptake and genomic integration.
• Non-viral gene therapy faces hurdles in nuclear localization and achieving sustained transgene expression.
• The retina presents a unique environment where overcoming non-viral gene delivery limitations may be feasible.

Conclusions:

• Non-viral gene therapy holds promise for retinal diseases, potentially overcoming limitations of viral vectors, such as gene size constraints.
• Developing efficient non-viral systems is crucial for advancing gene-based treatments for untreatable blindness.
• Harnessing molecular techniques to create artificial systems that match viral efficiency is key to future retinal gene therapy success.